PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-16.18%
G&A reduction while TRAW shows 8.73% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses change of 7.12% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
-22.68%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-22.68%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A growth while TRAW reduces D&A. John Neff would investigate differences.
22.73%
EBITDA growth exceeding 1.5x TRAW's 4.43%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Operating income growth exceeding 1.5x TRAW's 4.46%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Other expenses growth less than half of TRAW's 62.32%. David Dodd would verify if advantage is sustainable.
22.99%
Pre-tax income growth exceeding 1.5x TRAW's 15.11%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
22.99%
Net income growth exceeding 1.5x TRAW's 11.91%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS growth below 50% of TRAW's 78.16%. Michael Burry would check for structural issues.
38.32%
Diluted EPS growth below 50% of TRAW's 78.16%. Michael Burry would check for structural issues.
24.80%
Share count reduction exceeding 1.5x TRAW's 303.31%. David Dodd would verify capital allocation.
24.80%
Diluted share reduction exceeding 1.5x TRAW's 303.31%. David Dodd would verify capital allocation.